H.C. Wainwright & Co. Research Update: “Upcoming Milestones Could Prove Transformative; Reiterate Buy and Raising Target to A$1.50”

Respected Wall Street analyst Dr Raghuram Selvaraju has published new research on Cynata: “Raising price target—anticipating further milestones near-term. We believe that Cynata is entering a catalyst-rich period, with the possible option exercise near-term in its arrangement with Fujifilm…”

Download Cynata Therapeutics Update